Nymox Reports 2006 Financial Results

HASBROUCK HEIGHTS, N.J. - Nymox Pharmaceutical Corporation has announced its financial results for the year ended December 31, 2006. Product sales increased by 3.0% and amounted to $437,440 for 2006, compared to $424,506 for 2005. Nymox reported a net loss of $4,893,685, or $0.18 per share for the year ended December 31, 2006, compared to $3,584,528, or $0.14 per share for 2005. 63% of the increase in net loss was attributable to accounting requirements for stock option compensation. The weighted, diluted average number of common shares at December 31, 2006 was 27,711,981, compared to 26,103,704 at December 31, 2005. Nymox currently has $11.0 million in financing available from its most recent financing.

Nymox has developed NX-1207, an innovative new treatment for BPH. The company’s completed Phase 2 trial showed positive efficacy and safety results for NX-1207. Overall, patients treated with NX-1207 showed mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 point reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.